Data di Pubblicazione:
2023
Citazione:
Esmethadone-HCl (REL-1017): a promising rapid antidepressant / M. Fava, S.M. Stahl, S. De Martin, A. Mattarei, E. Bettini, S. Comai, A. Alimonti, F. Bifari, L. Pani, F. Folli, C. Guidetti, A. Furlan, J. Sgrignani, P. Locatelli, A. Cavalli, C. O'Gorman, S. Traversa, C.E. Inturrisi, M. Pappagallo, P.L. Manfredi. - In: EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE. - ISSN 0940-1334. - (2023), pp. 1-14. [Epub ahead of print] [10.1007/s00406-023-01571-4]
Abstract:
This review article presents select recent studies that form the basis for the development of esmethadone into a potential new drug. Esmethadone is a promising member of the pharmacological class of uncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonists that have shown efficacy for major depressive disorder (MDD) and other diseases and disorders, such as Alzheimer's dementia and pseudobulbar affect. The other drugs in the novel class of NMDAR antagonists with therapeutic uses that are discussed for comparative purposes in this review are esketamine, ketamine, dextromethorphan, and memantine. We present in silico, in vitro, in vivo, and clinical data for esmethadone and other uncompetitive NMDAR antagonists that may advance our understanding of the role of these receptors in neural plasticity in health and disease. The efficacy of NMDAR antagonists as rapid antidepressants may advance our understanding of the neurobiology of MDD and other neuropsychiatric diseases and disorders.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Esketamine; Esmethadone; Ketamine; Major depressive disorder; N-Methyl-D-aspartate receptor; REL-1017
Elenco autori:
M. Fava, S.M. Stahl, S. De Martin, A. Mattarei, E. Bettini, S. Comai, A. Alimonti, F. Bifari, L. Pani, F. Folli, C. Guidetti, A. Furlan, J. Sgrignani, P. Locatelli, A. Cavalli, C. O'Gorman, S. Traversa, C.E. Inturrisi, M. Pappagallo, P.L. Manfredi
Link alla scheda completa: